ALZAMEND NEURO, INC. Convertible Notes Payable
ALZAMEND NEURO, INC. (ALZN) had Convertible Notes Payable of $344.89 thousand as of 2021-10-31, per its 10-Q filed 2021-12-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleNotesPayable · last filed 2022-07-19
- 2021-10-31: Convertible Notes Payable $344.89K.
- 2021-07-31: Convertible Notes Payable $340.10K.
- 2021-04-30: Convertible Notes Payable $335.30K.
| Period end | Convertible Notes Payable |
|---|---|
| 2021-10-31 | $344.89K 10-Q · filed 2021-12-13 |
| 2021-07-31 | $340.10K 10-Q · filed 2021-09-13 |
| 2021-04-30 | $335.30K 10-K · filed 2022-07-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |